Safety and effectiveness of setmelanotide in young patients with severe obesity due to craniopharyngioma: a real world monocentric experience.
Oana Ruxandra Cotta, Cesare Morgante, Annalisa Giandalia et al.
✦ AI-curated · Sources linked
Case in brief
Three young adults with hypothalamic obesity following surgery for craniopharyngioma were treated with setmelanotide. While one patient experienced continued weight gain and discontinued treatment, the other two showed significant improvements in weight, BMI, waist circumference, triglycerides, and insulin levels over a period of 6-9 months. Adverse effects were mild and did not hinder treatment.
Diagnostic / clinical pearl
Setmelanotide may be beneficial for select patients with severe hypothalamic obesity post-craniopharyngioma surgery, though responses can vary significantly.
Why it matters
This case highlights the potential of targeted therapies like setmelanotide in managing treatment-refractory obesity, warranting further research in this area.